Is the stepping‐down approach a better option than multiple daily injections in obese patients with poorly controlled Type 2 diabetes on advanced insulin therapy?

Is the stepping‐down approach a better option than multiple daily injections in obese patients with poorly controlled Type 2 diabetes on advanced insulin therapy?

Abstract Aim To determine whether de‐escalating from advanced insulin therapy (AIT) to the combined use of metformin, an SGLT2 inhibitor, a GLP1 receptor agonist and basal insulin is the better option than multiple daily insulin injections (MDI) in obese patients with poorly controlled T2DM. Methods...

Full description

Bibliographic Details
Main Authors: Soe Naing, Geeta Ramesh, Jasmine Garcha, Anupama Poliyedath, Stutee Khandelwal, Paul K. Mills
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Endocrinology, Diabetes & Metabolism
Subjects:
GLP‐1 analogue
glycaemic control
insulin therapy
SGLT2 inhibitor
type 2 diabetes
Online Access:https://doi.org/10.1002/edm2.204

Internet

https://doi.org/10.1002/edm2.204

Similar Items